|
Selvita participates in ProcureCon Pharma 2012 |
|
Place: 28 - 29 February 2012, Zurich, Switzerland
Procurecon Pharma 2012 is an exciting new pharmaceutical procurement conference focusing on the strategic issues and challenges facing senior pharmaceutical & biotech sourcing professionals. This two-day pharmaceutical sourcing conference will be an open forum for networking, benchmarking and ideas sharing among Europe?s leading heads of procurement working in the biotechnology and pharmaceutical sectors.
To contact Selvita's delegate at this conference please send an email at:
This e-mail address is being protected from spam bots, you need JavaScript enabled to view it
|
|
|
Selvita presents at The 14th Annual BIO CEO & Investor Conference |
Place: 13th - 14th February 2012, New York, USA
The BIO CEO & Investor Conference is the largest investor conference focused on established and emerging publicly traded biotech companies. It's mission is to support industry-wide success, and present a broad and unbiased view of investment opportunities.
BIO One-on-One Partnering provides an opportunity to arrange meetings between investors; companies; and industry BD, licensing and therapeutic franchise heads.
Selvita will present at this conference, on Tuesday, February 14, at 1:00 pm (ECT), in the Conrad Room.
To contact Selvita's delegate at this conference please send an email at:
This e-mail address is being protected from spam bots, you need JavaScript enabled to view it
Read more about the conference
|
|
|
Selvita presents at the 5th Annual European Life Science CEO Forum for Partnering & Investing |
Place: 5th-6th March, 2012, Zurich, Switzerland
The 5th Annual European Life Sciences CEO Forum for Partnering & Investing is recognised as a leading international stage for those interested in investing in the Life Science and Biotech industries and is highly transactional. It draws together an exciting cross-section of early-stage/pre-IPO, late-stage and public companies with leading investors, analysts, money managers and pharmas. Following the success of last years' Life Sciences forum, we aim to expand the audience and provide, once again, opportunities for executive-level networking, deal-making and partnering.
Selvita will also hold a presentation during this event, details of which will be announced soon.
To contact Selvita's delegate at this conference please email at:
This e-mail address is being protected from spam bots, you need JavaScript enabled to view it
Read more about the conference
|
|
|
Selvita presents at BIO-Europe Spring 2012 |
Location: 19th - 21st March 2012, Amsterdam, The Netherlands
BIO-Europe is Europe's largest partnering conference, serving the global biotechnology industry. The conference annually attracts leading dealmakers from biotech, pharma and finance along with the most exciting emerging companies. Produced with the support of BIO, it is regarded as a "must attend" event for the biotech industry.
BIO-Europe Spring 2012 event will bring together international decision-makers from all sectors of the biotechnology industry, and features the successful combination of One-to-One meetings, company presentations, panel discussions and a lively exhibition.
Selvita will present during the conference in the "Cancer" session. Details of the presentation will be announced soon.
To request a meeting with any of Selvita's delegates at BIO-Europe Spring 2012 please kindly send an e-mail to
This e-mail address is being protected from spam bots, you need JavaScript enabled to view it
Read more about the conference
|
|
|
Selvita released the most recent results from its oncology programs at the 2011 AACR-EORTC-NCI |
October 24, 2011, Krakow, Poland - Selvita, Polish biotechnology company engaged in the discovery and development of breakthrough medicines to treat CNS and oncology disorders, as well as provision of non-clinical research services,presented data from two of its oncology programs at the 2011 AACR-EORTC-NCI Molecular Targets and Cancer Therapeutics Conference, November 12-16, 2011, in San Francisco, CA, USA.
Data presented during this conference included new results from the SEL24 program, a group of specific inhibitors of Pim-1 kinase, as well as the first data from SEL120 program, a potentially first in class kinase inhibitor.
A poster presentation entitled "Novel Pim kinase inhibitors for treatment of hematological malignancies and solid tumors" was presented at the poster session A, titled "Therapeutic Agents: Small Molecule Kinase Inhibitors 1" on Sunday, November 13th, 2011 (Abstract #: A243)
A poster presentation entitled "Antitumor activity of SEL120: An orally available small-molecule inhibitor of Haspin kinase, for standalone and combination therapy with AuroraB inhibitors in colorectal cancer" was presented at the poster session B, titled "Therapeutic Agents: Small Molecule Kinase Inhibitors 2" Monday, November 14th, 2011 (Abstract # B242).
"Current and further development of both SEL24 and SEL120 program, presented at the AACR-EORTC-NCI conference, was made possible thanks to the substantial investment received by Selvita through private placement and the debut on the NewConnect market in July 2011 - said Dr Nicolas Beuzen, Selvita's Chief Scientific Officer. SEL24 is currently at the lead optimization stage, with first clinical trials to be initiated in 2012, while SEL120 is currently in the early phase of discovery research. Selvita's strategy assumes sales of both programs, SEL24 in 2012 and SEL120 in the following years, which will allow the company to break-even in 2012."
To download the poster please click here
|
|
|
